Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib in Japanese Patients with Myelofibrosis
NCT01692366Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of fedratinib in myelofibrosis (MF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Response Rate (RR), defined as the proportion of subjects who have a ≥35% reduction in spleen volume at 24 weeks. Started Nov 2012; status: completed.
02
Drugs
fedratinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT01692366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01692366.